Brief: Odonate Therapeutics Announces Completion Of Enrollment In CONTESSA
21/10/2019 13:35
Oct 21 (Reuters) - Odonate Therapeutics Inc ODT.O :
* ODONATE THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
CONTESSA, A PHASE 3 STUDY OF TESETAXEL IN PATIENTS WITH
METASTATIC BREAST CANCER
Source text for Eikon: ID:nBw8QDwnsa
Further company coverage: ODT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Odonate
See all newsBrief: Odonate Announces Expected Delisting Of Its Stock
Brief: Odonate Therapeutics Announces Planned Return Of Capital To Stockholders Through Share Repurchase Plan
Brief: Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58
Odonate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview